Amedeo Smart

Free Medical Literature Service

 

Amedeo

Head and Neck Cancer
  Free Subscription

Articles published in
J Clin Endocrinol Metab
    June 2025
  1. YAMAZAKI H, Sugino K, Katoh R, Matsuzu K, et al
    Clinical Significance of Successful Ablation in Follicular Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2025 Jun 4:dgaf326. doi: 10.1210.
    >> Share

    May 2025
  2. FRICH PS, Sigstad E, Berstad AE, Opsahl EM, et al
    Ethanol Ablation of Metastatic Lymph Nodes in Patients with Papillary Thyroid Carcinoma - Predictors of Clinical Outcome.
    J Clin Endocrinol Metab. 2025 May 23:dgaf298. doi: 10.1210.
    >> Share

    March 2025
  3. SHARIQ OA, Waguespack SG, Hamidi S, Kensing BC, et al
    Approach to the Patient: Hereditary Medullary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2025 Mar 19:dgaf089. doi: 10.1210.
    >> Share

  4. SIMONDS WF, Li Y, Jha S
    Genotype-Phenotype Correlations in the Hyperparathyroidism-Jaw Tumor Syndrome.
    J Clin Endocrinol Metab. 2025;110:931-939.
    >> Share

    February 2025
  5. SCAPPATICCIO L, Di Martino N, Ferrazzano P, Maiorino MI, et al
    Prevalence and Management of Complications of Laser Ablation for Benign Thyroid Nodules: A Systematic Review of Literature and Meta-analysis.
    J Clin Endocrinol Metab. 2025 Feb 20:dgaf108. doi: 10.1210.
    >> Share

  6. GOLDFARB M, Bustos MA, Moon J, Jackson K, et al
    Pilot Study of Plasma miRNA Signature Panel for Differentiating Single vs Multiglandular Parathyroid Disease.
    J Clin Endocrinol Metab. 2025;110:758-770.
    >> Share

  7. ZHOU J, Li D, Ren J, Huang C, et al
    Machine Learning: A Multicentre Study on Predicting Lateral Lymph Node Metastasis in cN0 Papillary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2025 Feb 8:dgaf070. doi: 10.1210.
    >> Share

  8. WANG L, Zhang L, Ma R, Zhang Y, et al
    Semaglutide reprograms macrophages via the GLP-1R/PPARG/ACSL1 pathway to suppress papillary thyroid carcinoma growth.
    J Clin Endocrinol Metab. 2025 Feb 5:dgaf053. doi: 10.1210.
    >> Share

    January 2025
  9. TELITI M, Chytiris S, Coperchini F, Cerutti M, et al
    The natural history of cytologically low-risk indeterminate thyroid nodules.
    J Clin Endocrinol Metab. 2025 Jan 29:dgaf052. doi: 10.1210.
    >> Share

  10. LI Y, Simonds WF, Chen H
    A Comparative Genomic Analysis of Parathyroid Adenomas and Carcinomas Harboring Heterozygous Germline CDC73 Mutations.
    J Clin Endocrinol Metab. 2025;110:429-440.
    >> Share

  11. NAKAI T, Horiuchi K, Okamoto T
    Predicting Tumor Volume in Primary Hyperparathyroidism From Preoperative Clinical Data.
    J Clin Endocrinol Metab. 2025;110:e391-e396.
    >> Share

  12. SONG JX, Dong YQ, Han RL, Xie J, et al
    PI3K/AKT/mTOR Activation is Associated with Malignant Severity and Poorer Prognosis in Parathyroid Carcinomas.
    J Clin Endocrinol Metab. 2025 Jan 20:dgaf042. doi: 10.1210.
    >> Share

  13. ROBENSHTOK E, Bachar G, Ritter A
    Approach to the Patient with Thyroid Cancer: Selection and Management of Candidates for Lobectomy.
    J Clin Endocrinol Metab. 2025 Jan 2:dgae903. doi: 10.1210.
    >> Share

    November 2024
  14. CHEN Z, Sun W, Fei M, Qian K, et al
    Clinical and Sonographic Differences between RET Fusion-Positive and BRAFV600E in Papillary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2024 Nov 18:dgae803. doi: 10.1210.
    >> Share


  15. Correction to: "Prognostic Analysis of 131I Efficacy After Papillary Thyroid Carcinoma Surgery Based on CT Radiomics".
    J Clin Endocrinol Metab. 2024 Nov 1:dgae756. doi: 10.1210.
    >> Share

    October 2024
  16. MENG L, Li H, Fu Y, Yu D, et al
    Somatic DICER1-Mutant Benign Thyroid Nodules in Adults: A Group of Follicular Nodular Disease With Continuous Growth.
    J Clin Endocrinol Metab. 2024 Oct 28:dgae750. doi: 10.1210.
    >> Share

  17. PARVATHAREDDY SK, Siraj AK, Qadri Z, Siraj N, et al
    The Prognostic Impact of Tumor Size and BRAF Mutational Status in Middle Eastern Differentiated Thyroid Cancer.
    J Clin Endocrinol Metab. 2024 Oct 18:dgae740. doi: 10.1210.
    >> Share


  18. Correction to: "Pediatric Papillary Thyroid Carcinoma: Outcomes After Surgery Without Adjuvant Radioactive Iodine".
    J Clin Endocrinol Metab. 2024 Oct 16:dgae717. doi: 10.1210.
    >> Share

  19. BEHAIRY N, Leonardi AJ, Gubbi S, Kumari S, et al
    Tumor Volume Doubling Time of Less Than One Year is Associated with a Higher Risk of Death from Medullary Thyroid Cancer.
    J Clin Endocrinol Metab. 2024 Oct 16:dgae733. doi: 10.1210.
    >> Share

  20. KELLY CA, Sipos JA
    Approach to the patient with thyroid nodules: considering GLP-1 receptor agonists.
    J Clin Endocrinol Metab. 2024 Oct 14:dgae722. doi: 10.1210.
    >> Share

  21. LEE S, Antunez AG, Sinco B, Saucke MC, et al
    Cancer-related Fear and Worry in Patients with Low-Risk Thyroid Cancer: A Longitudinal Cohort Study.
    J Clin Endocrinol Metab. 2024 Oct 14:dgae688. doi: 10.1210.
    >> Share

  22. HSU YC, Kuo CY, Chien MN, Jhuang JY, et al
    Overexpression of NR1D1 portends disease recurrence in thyroid cancer.
    J Clin Endocrinol Metab. 2024 Oct 3:dgae687. doi: 10.1210.
    >> Share

  23. MEHANNA H, Nankivell P, Boelaert K, Woolley R, et al
    Diagnostic performance of ultrasound vs. ultrasound-guided FNAc in thyroid nodules: data from the ElaTION trial.
    J Clin Endocrinol Metab. 2024 Oct 3:dgae682. doi: 10.1210.
    >> Share

  24. ROTONDI M, Endo M, Teliti M, Crescenzi A, et al
    Beyond malignancy risk stratification: FNAC report anticipates thyroid cancer staging. Insights from recent studies.
    J Clin Endocrinol Metab. 2024 Oct 1:dgae675. doi: 10.1210.
    >> Share

    September 2024
  25. MORETTI S, Mandarano M, Menicali E, Guzzetti M, et al
    Wnt/B-catenin activation and TP53 mutations associate with distinct immune profiles in advanced thyroid cancer.
    J Clin Endocrinol Metab. 2024 Sep 27:dgae667. doi: 10.1210.
    >> Share

  26. XU B, Baine MK, Jungbluth A, Alabkaa A, et al
    Detection of SEZ6, a therapeutic target, in medullary thyroid carcinoma.
    J Clin Endocrinol Metab. 2024 Sep 26:dgae672. doi: 10.1210.
    >> Share

  27. ZHANG Y, Zhang X, Lin L, Xing M, et al
    Efficacy and safety of targeted therapy for radioiodine-refractory differentiated thyroid cancer: a meta-analysis.
    J Clin Endocrinol Metab. 2024 Sep 18:dgae617. doi: 10.1210.
    >> Share

  28. MACIEL AAW, Danilovic DLS, Soares IC, Freitas TC, et al
    Association between papillary thyroid cancer and primary aldosteronism in individuals with hypertension.
    J Clin Endocrinol Metab. 2024 Sep 18:dgae653. doi: 10.1210.
    >> Share

    August 2024
  29. YUAN J, Chen Z, Zhang J, Chen X, et al
    Preoperative Serum Lipids as Novel Predictors of Survival in 3575 Papillary Thyroid Cancer Patients.
    J Clin Endocrinol Metab. 2024 Aug 30:dgae601. doi: 10.1210.
    >> Share

  30. MOOIJ CF, Zwaveling-Soonawala N, Hillebrand JJ, van Trotsenburg ASP, et al
    Approach to the Patient: Challenging Cases of Pediatric Thyrotoxicosis.
    J Clin Endocrinol Metab. 2024 Aug 27:dgae592. doi: 10.1210.
    >> Share

  31. RAMONE T, Ghirri A, Prete A, Matrone A, et al
    Molecular profiling of low-risk papillary thyroid carcinoma (mPTC) on active surveillance.
    J Clin Endocrinol Metab. 2024 Aug 24:dgae575. doi: 10.1210.
    >> Share

  32. XU Y, Gao J, Wang N, Zedenius J, et al
    BRAF-induced EHF expression affects TERT in aggressive papillary thyroid cancer.
    J Clin Endocrinol Metab. 2024 Aug 24:dgae589. doi: 10.1210.
    >> Share

  33. STEGENGA MT, Oudijk L, van Velsen EFS, Peeters RP, et al
    Impact of Reclassification of Oncocytic and Follicular Thyroid Carcinoma by the 2022 WHO Classification.
    J Clin Endocrinol Metab. 2024 Aug 21:dgae581. doi: 10.1210.
    >> Share

  34. CASTELLANOS LE, Zafereo ME, Sturgis EM, Wang JR, et al
    Pediatric Papillary Thyroid Carcinoma: Outcomes After Surgery Without Adjuvant Radioactive Iodine.
    J Clin Endocrinol Metab. 2024 Aug 20:dgae576. doi: 10.1210.
    >> Share

  35. GRANI G, D'Elia S, Puxeddu E, Morelli S, et al
    Data-Driven Thyroglobulin Cutoffs for Low- and Intermediate-Risk Thyroid Cancer Follow-Up: ITCO Real-World Analysis.
    J Clin Endocrinol Metab. 2024 Aug 16:dgae559. doi: 10.1210.
    >> Share

  36. IYER PC, Dadu R, Barque A, Zanelli C, et al
    Analytical Validation of a Telomerase Reverse Transcriptase (TERT) Promoter Mutation Assay.
    J Clin Endocrinol Metab. 2024;109:2269-2273.
    >> Share

  37. LI G, Ye Z, Wei T, Zhu J, et al
    Clinical Outcomes and Implications of Radioactive Iodine Therapy on Cancer-specific Survival in WHO Classification of FTC.
    J Clin Endocrinol Metab. 2024;109:2294-2305.
    >> Share

  38. ENDO M, Peng J, Nabhan FA, Brock P, et al
    Indolent Behavior of Malignant Bethesda III Nodules Compared to Bethesda V/VI Nodules.
    J Clin Endocrinol Metab. 2024;109:2317-2324.
    >> Share

  39. KONDA B, Sherman EJ, Massarelli E, Nieva J, et al
    Cabozantinib plus ipilimumab/nivolumab in patients with previously treated advanced differentiated thyroid cancer.
    J Clin Endocrinol Metab. 2024 Aug 12:dgae512. doi: 10.1210.
    >> Share

  40. GHOSH R, Auh S, Gubbi S, Veeraraghavan P, et al
    Association of Free Thyroxine with Progression-Free Survival in Intermediate and High Risk Differentiated Thyroid Cancer.
    J Clin Endocrinol Metab. 2024 Aug 8:dgae537. doi: 10.1210.
    >> Share

  41. WANG JR, Zafereo ME, Cabanillas ME, Wu CC, et al
    The association between thyroid differentiation score and survival outcomes in papillary thyroid carcinoma.
    J Clin Endocrinol Metab. 2024 Aug 1:dgae532. doi: 10.1210.
    >> Share

    July 2024
  42. FENG J, Wu C, Shen F, Cai W, et al
    Second Primary Differentiated Thyroid Carcinoma in Adult Cancer Survivors: A SEER Database Analysis.
    J Clin Endocrinol Metab. 2024 Jul 24:dgae501. doi: 10.1210.
    >> Share

  43. WANG H, Li Q, Tian T, Liu B, et al
    Improving the Risk Prediction of the 2015 ATA Recurrence Risk Stratification in Papillary Thyroid Cancer.
    J Clin Endocrinol Metab. 2024 Jul 9:dgae465. doi: 10.1210.
    >> Share

  44. JING R, Wu N, Wu Y, Zhang Q, et al
    Efficacy and safety of multikinase inhibitors for patients with refractory thyroid cancer: Systematic review and network meta-analysis.
    J Clin Endocrinol Metab. 2024 Jul 6:dgae454. doi: 10.1210.
    >> Share


  45. Correction to: "TERT Promoter Mutations Increase Tumor Aggressiveness by Altering TERT mRNA Splicing in Papillary Thyroid Carcinoma".
    J Clin Endocrinol Metab. 2024 Jul 1:dgae442. doi: 10.1210.
    >> Share

    June 2024
  46. SEHGAL K, Serritella A, Liu M, ONeill A, et al
    A phase I/II trial of sapanisertib in advanced anaplastic and radioiodine refractory differentiated thyroid carcinoma.
    J Clin Endocrinol Metab. 2024 Jun 29:dgae443. doi: 10.1210.
    >> Share

  47. PARDI E, Poma AM, Torregrossa L, Pierotti L, et al
    Whole-exome sequencing of atypical parathyroid tumors detects novel and common genes linked to parathyroid tumorigenesis.
    J Clin Endocrinol Metab. 2024 Jun 28:dgae441. doi: 10.1210.
    >> Share

  48. WILLIAMS MD, Liu Z, Rossi ED, Agarwal S, et al
    Seven years of Non-invasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP): Rate of Acceptance and Variation of Diagnostic Approaches Across Different Continents.
    J Clin Endocrinol Metab. 2024 Jun 14:dgae354. doi: 10.1210.
    >> Share

    May 2024
  49. CAO H, Shangguan L, Zhu H, Hu C, et al
    Prognostic analysis of 131I efficacy after papillary thyroid carcinoma surgery based on CT radiomics.
    J Clin Endocrinol Metab. 2024 May 27:dgae364. doi: 10.1210.
    >> Share

  50. LEVESQUE F, Payne RJ, Beaudoin D, Boucher A, et al
    A Prospective Study of Publicly Funded Molecular Testing of Indeterminate Thyroid Nodules: Canada's Experience.
    J Clin Endocrinol Metab. 2024 May 23:dgae355. doi: 10.1210.
    >> Share

  51. LI G, Chen W, Jiang K, Huang J, et al
    Exosome-mediated Delivery of miR-519e-5p Promotes Malignant Tumor Phenotype and CD8+ T-Cell Exhaustion in Metastatic PTC.
    J Clin Endocrinol Metab. 2024;109:1601-1617.
    >> Share

  52. XIAN K, Xu S, Huang H, Xing C, et al
    Synergy of nodal factors in predicting recurrence after treatment of N1b papillary thyroid carcinoma.
    J Clin Endocrinol Metab. 2024 May 15:dgae329. doi: 10.1210.
    >> Share

  53. ZHANG W, Lin S, Wang Z, Zhang W, et al
    Coexisting RET/PTC and TERT Promoter Mutation Predict Poor Prognosis but Effective RET and MEK Targets in Thyroid Cancer.
    J Clin Endocrinol Metab. 2024 May 13:dgae327. doi: 10.1210.
    >> Share

    April 2024
  54. PETROVIC I, LoPresti J, Fatemi S, Gianoukakis A, et al
    Influence of Thyroglobulin (Tg) Autoantibodies on Tg levels Measured by Different Methodologies: (IMA, LC-MS/MS and RIA).
    J Clin Endocrinol Metab. 2024 Apr 30:dgae286. doi: 10.1210.
    >> Share

  55. SANT VR, Radhachandran A, Ivezic V, Lee DT, et al
    From Bench-to-Bedside: How Artificial Intelligence Is Changing Thyroid Nodule Diagnostics.
    J Clin Endocrinol Metab. 2024 Apr 29:dgae277. doi: 10.1210.
    >> Share

  56. ABOU AZAR S, Tobias J, Applewhite M, Angelos P, et al
    Medullary Thyroid Cancer: Single Institute Experience over Three Decades and Risk Factors for Recurrence.
    J Clin Endocrinol Metab. 2024 Apr 23:dgae279. doi: 10.1210.
    >> Share

  57. CHO YY, Ahn SH, Lee EK, Park YJ, et al
    Malignancy Risk of Follicular Neoplasm (Bethesda IV) With Variable Cutoffs of Tumor Size: A Systemic Review and Meta-Analysis.
    J Clin Endocrinol Metab. 2024;109:1383-1392.
    >> Share

  58. TODA S, Hiroshima Y, Iwasaki H, Masudo K, et al
    Genomic landscape and clinical features of advanced thyroid carcinoma: a national database study in Japan.
    J Clin Endocrinol Metab. 2024 Apr 17:dgae271. doi: 10.1210.
    >> Share

  59. SAKO A, Matsuse M, Saenko V, Tanaka A, et al
    TERT promoter mutations increase tumor aggressiveness by altering TERT mRNA splicing in papillary thyroid carcinoma.
    J Clin Endocrinol Metab. 2024 Apr 5:dgae220. doi: 10.1210.
    >> Share

  60. LIU CQ, Shen CK, Du YX, Li ZM, et al
    Survival outcome and optimal candidates of primary tumor resection for patients with metastatic medullary thyroid cancer.
    J Clin Endocrinol Metab. 2024 Apr 4:dgae214. doi: 10.1210.
    >> Share

    March 2024
  61. LEE-SAXTON YJ, Egan CE, Bratton BA, Thiesmeyer JW, et al
    Low Mitotic Activity in Papillary Thyroid Cancer: A Marker for Aggressive Features and Recurrence.
    J Clin Endocrinol Metab. 2024 Mar 30:dgae203. doi: 10.1210.
    >> Share

  62. MAROTTA V, Rocco D, Crocco A, Deiana MG, et al
    Survival predictors of radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the real-life.
    J Clin Endocrinol Metab. 2024 Mar 19:dgae181. doi: 10.1210.
    >> Share

  63. OHIRA T, Nagao M, Hayashi F, Shimura H, et al
    Effects of Overweight on Risk of Thyroid Nodules in Children and Adolescents: The Fukushima Health Management Survey.
    J Clin Endocrinol Metab. 2024 Mar 13:dgae161. doi: 10.1210.
    >> Share

  64. CHEN H, Liu Y, Wang F, Sun J, et al
    MeIS: DNA methylation-based immune response signatures for thyroid nodule diagnostics.
    J Clin Endocrinol Metab. 2024 Mar 7:dgae141. doi: 10.1210.
    >> Share

  65. HENSLEY SG, Hu MI, Bassett RL, Ying AK, et al
    Pediatric Medullary Thyroid Carcinoma: Clinical Presentations and Long-term Outcomes in 144 Patients Over Six Decades.
    J Clin Endocrinol Metab. 2024 Mar 4:dgae133. doi: 10.1210.
    >> Share

    February 2024
  66. JAGANNATH S, Mayilvaganan S
    Letter to the Editor from Jagannath and Mayilvaganan: "Is Multifocality a Predictor of Poor Outcome in Childhood and Adolescent Papillary Thyroid Carcinoma".
    J Clin Endocrinol Metab. 2024 Feb 29:dgae117. doi: 10.1210.
    >> Share

  67. SARKAR R, Bolel P, Kapoor A, Eliseeva E, et al
    An Orally Efficacious Thyrotropin Receptor Ligand Inhibits Growth and Metastatic Activity of Thyroid Cancers.
    J Clin Endocrinol Metab. 2024 Feb 29:dgae114. doi: 10.1210.
    >> Share

  68. SCHOLFIELD DW, Lopez J, Eagan A, Antal Z, et al
    Response to Letter to the Editor from Jagannath and Mayilvaganan: "Is Multifocality a Predictor of Poor Outcome in Childhood and Adolescent Papillary Thyroid Carcinoma?".
    J Clin Endocrinol Metab. 2024 Feb 28:dgae118. doi: 10.1210.
    >> Share

  69. AHMADI S, Kotwal A, Bikas A, Xiang P, et al
    Outcomes of cytologically indeterminate thyroid nodules managed with Genomic Sequencing Classifier.
    J Clin Endocrinol Metab. 2024 Feb 28:dgae112. doi: 10.1210.
    >> Share

  70. VAN DER TUIN K, Ruano D, Knijnenburg J, van der Luijt RB, et al
    Clinically-relevant Germline Variants in Children with Non-Medullary Thyroid Cancer.
    J Clin Endocrinol Metab. 2024 Feb 28:dgae107. doi: 10.1210.
    >> Share

  71. MAINO F, Botte M, Dalmiglio C, Valerio L, et al
    Prognostic Factors Improving ATA Risk System and Dynamic Risk Stratification in Low- and Intermediate-Risk DTC Patients.
    J Clin Endocrinol Metab. 2024;109:722-729.
    >> Share

  72. STEGENGA MT, van Velsen EFS, Oudijk L, Verburg FA, et al
    Clinical and Histopathological Risk Factors for Radioactive Iodine Refractory Follicular and Oncocytic Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2024 Feb 13:dgae084. doi: 10.1210.
    >> Share

  73. ALTSHULER B, Bikas A, Pappa T, Marqusee E, et al
    Non-Operative, Active Surveillance of Larger Malignant and Suspicious Thyroid Nodules.
    J Clin Endocrinol Metab. 2024 Feb 13:dgae082. doi: 10.1210.
    >> Share

    January 2024
  74. CONDELLO V, Poma AM, Macerola E, Vignali P, et al
    Prevalence, Molecular Landscape and Clinical Impact of DICER1 and DGCR8 Mutated Follicular-Patterned Thyroid Nodules.
    J Clin Endocrinol Metab. 2024 Jan 22:dgae034. doi: 10.1210.
    >> Share

  75. BHARADWAJ MS, Ballal S, Bal C
    Optimal Cumulative I-131 Activity in Metastatic Differentiated Thyroid Cancer: Balancing Efficacy and Adverse Events.
    J Clin Endocrinol Metab. 2024 Jan 12:dgae024. doi: 10.1210.
    >> Share

  76. BUCZYNSKA A, Kosciuszko M, Sidorkiewicz I, Wiatr AA, et al
    Enhancing Angioinvasion Assessment in Papillary Thyroid Cancer via a Biomarker Panel Involving TAC, 8-OHdG and Sortilin.
    J Clin Endocrinol Metab. 2024 Jan 5:dgae007. doi: 10.1210.
    >> Share

    December 2023
  77. KIM BH, Ryu SR, Lee JW, Song CM, et al
    Longitudinal changes in quality of life before and after thyroidectomy in patients with differentiated thyroid cancer.
    J Clin Endocrinol Metab. 2023 Dec 23:dgad748. doi: 10.1210.
    >> Share

  78. PAPARODIS R, Livadas S, Karvounis E, Bantouna D, et al
    Elevated Preoperative TPO Ab Titers Decrease Risk for DTC in a Linear Fashion: A Retrospective Analysis of 1635 Cases.
    J Clin Endocrinol Metab. 2023;109:e347-e355.
    >> Share

  79. GOLDNER W
    The Role of Age in the Risk Assessment of Differentiated Thyroid Cancers.
    J Clin Endocrinol Metab. 2023 Dec 20:dgad743. doi: 10.1210.
    >> Share

  80. LIN S, Wang Z, Xing M
    Association between a History of Breast Cancer and Decreased Thyroid Cancer-specific Mortality.
    J Clin Endocrinol Metab. 2023 Dec 8:dgad722. doi: 10.1210.
    >> Share

  81. MU Z, Zhang X, Sun D, Sun Y, et al
    Characterizing genetic alterations related to radioiodine avidity in metastatic thyroid cancer.
    J Clin Endocrinol Metab. 2023 Dec 7:dgad697. doi: 10.1210.
    >> Share

  82. LEUNG AM, Brent GA
    Pregnancy - Does Promotion of Growth Extend to Thyroid Cancer?
    J Clin Endocrinol Metab. 2023 Dec 2:dgad707. doi: 10.1210.
    >> Share

  83. WANG Y, Zou B, Zhang Y, Zhang J, et al
    Comprehensive long-read sequencing analysis discloses the transcriptome features of Papillary Thyroid Microcarcinoma.
    J Clin Endocrinol Metab. 2023 Dec 1:dgad695. doi: 10.1210.
    >> Share

    November 2023
  84. YAMAZAKI H, Sugino K, Katoh R, Matsuzu K, et al
    Role of the degree of vascular invasion in predicting prognosis of follicular thyroid carcinoma.
    J Clin Endocrinol Metab. 2023 Nov 25:dgad689. doi: 10.1210.
    >> Share

  85. TORA R, Welch J, Sun J, Agarwal SK, et al
    Phenotypic Profiling and Molecular Mechanisms in Hyperparathyroidism-jaw Tumor Syndrome.
    J Clin Endocrinol Metab. 2023;108:3165-3177.
    >> Share

  86. LIU Q, Mao L, Zhang Z, Li G, et al
    Diagnostic Efficacy of FNA-Tg in DTC Cervical LN Metastasis and its Impact Factors: A Large Retrospective Study.
    J Clin Endocrinol Metab. 2023;108:3311-3319.
    >> Share

  87. FALCHETTI A
    New Perspective on the Genetic Dissection Underlying the Development of Parathyroid Cancer.
    J Clin Endocrinol Metab. 2023;108:e1751-e1752.
    >> Share

  88. LI P, Liu Y, Wei T, Wang X, et al
    Effect and interactions of BRAF on lymph node metastasis in papillary thyroid carcinoma with Hashimoto's thyroiditis.
    J Clin Endocrinol Metab. 2023 Nov 15:dgad667. doi: 10.1210.
    >> Share

    October 2023
  89. KWON H, Han KD, Moon SJ, Park SE, et al
    Nonalcoholic Fatty Liver Disease and the Risk of Thyroid Cancer Among Young Adults in South Korea.
    J Clin Endocrinol Metab. 2023 Oct 31:dgad575. doi: 10.1210.
    >> Share

  90. DAI P, Zhao W, Zheng X, Luo H, et al
    Effect of radioactive iodine therapy on cancer-specific survival of papillary thyroid cancer tall cell variant.
    J Clin Endocrinol Metab. 2023 Oct 7:dgad580. doi: 10.1210.
    >> Share


  91. Correction to "The Outcomes of First Reoperation for Locoregionally Recurrent/Persistent Papillary Thyroid Carcinoma in Patients Who Initially Underwent Total Thyroidectomy and Remnant Ablation".
    J Clin Endocrinol Metab. 2023 Oct 3:dgad573. doi: 10.1210.
    >> Share

    September 2023
  92. PALYGA I, Rumian M, Kosel A, Albrzykowski M, et al
    The frequency of differentiated thyroid cancer recurrence in 2302 patients with excellent response to primary therapy.
    J Clin Endocrinol Metab. 2023 Sep 28:dgad571. doi: 10.1210.
    >> Share

  93. XIAO WC, Li X, Shan R, Mei F, et al
    Pregnancy and progression of differentiated thyroid cancer: A propensity score-matched retrospective cohort study.
    J Clin Endocrinol Metab. 2023 Sep 20:dgad557. doi: 10.1210.
    >> Share

  94. POZDEYEV N, Dighe M, Barrio M, Raeburn C, et al
    Thyroid cancer polygenic risk score improves classification of thyroid nodules as benign or malignant.
    J Clin Endocrinol Metab. 2023 Sep 8:dgad530. doi: 10.1210.
    >> Share

  95. ILGAN S, Aydogan BI, Emer O, Anil C, et al
    Sonographic features of atypical and initially missed parathyroid adenomas: Lessons learned from a single center cohort.
    J Clin Endocrinol Metab. 2023 Sep 5:dgad527. doi: 10.1210.
    >> Share

    August 2023
  96. GILLIS A, Chen H, Wang TS, Dream S, et al
    Racial and Ethnic Disparities in the Diagnosis and Treatment of Thyroid Disease: a Mini- Review.
    J Clin Endocrinol Metab. 2023 Aug 30:dgad519. doi: 10.1210.
    >> Share

  97. HA EJ, Lee JH, Lee DH, Moon J, et al
    Artificial Intelligence Model Assisting Thyroid Nodule Diagnosis and Management: A Multicenter Diagnostic Study.
    J Clin Endocrinol Metab. 2023 Aug 25:dgad503. doi: 10.1210.
    >> Share

  98. JU G, Sun Y, Wang H, Zhang X, et al
    Fusion oncogenes in patients with locally advanced or distant metastatic differentiated thyroid cancer.
    J Clin Endocrinol Metab. 2023 Aug 25:dgad500. doi: 10.1210.
    >> Share

  99. LI H, Han R, Meng L, Sun Y, et al
    Nodal Metastases Associated with Fusion Oncogenes Are Age Dependent in Young Adult Patients with Thyroid Cancer.
    J Clin Endocrinol Metab. 2023 Aug 3:dgad458. doi: 10.1210.
    >> Share

    July 2023
  100. MERCADO M
    The Role of Androgen Receptors in Thyroid Cancer Biology: Beyond Sexual Dimorphism.
    J Clin Endocrinol Metab. 2023 Jul 15:dgad424. doi: 10.1210.
    >> Share

  101. NOEL JE, Sinclair CF
    Radiofrequency Ablation for Benign Thyroid Nodules.
    J Clin Endocrinol Metab. 2023 Jul 4:dgad357. doi: 10.1210.
    >> Share

    June 2023
  102. YAN L, Zhen Y, Li Y, Li X, et al
    Five-year Outcome Between Radiofrequency Ablation vs. Surgery for Unilateral Multifocal Papillary Thyroid Microcarcinoma.
    J Clin Endocrinol Metab. 2023 Jun 15:dgad360. doi: 10.1210.
    >> Share

  103. YEH MW
    The molecular landscape of thyroid nodules: Diagnostic and prognostic revelations from a large multicenter cohort.
    J Clin Endocrinol Metab. 2023 Jun 15:dgad362. doi: 10.1210.
    >> Share

  104. SATAPATHY S, Majeed AK, Ballal S, Bal C, et al
    Differentiated thyroid cancers in young adults versus children: Clinical characteristics and ten-year follow-up outcomes.
    J Clin Endocrinol Metab. 2023 Jun 7:dgad343. doi: 10.1210.
    >> Share

  105. ZHOU Y, Wang Y, Zhang Z, Yin X, et al
    Male sex is not a risk factor for prognosis in postoperative thyroid cancer patients: a propensity score matching study.
    J Clin Endocrinol Metab. 2023 Jun 2:dgad314. doi: 10.1210.
    >> Share

  106. BOJARSKY M, Baran JA, Halada S, Isaza A, et al
    Outcomes of ATA Low-Risk Pediatric Thyroid Cancer Patients Not Treated with Radioactive Iodine Therapy.
    J Clin Endocrinol Metab. 2023 Jun 2:dgad322. doi: 10.1210.
    >> Share

    May 2023
  107. LIN Y, Wu ZR, Shi YP, Ding M, et al
    Radiofrequency Ablation of Unifocal Papillary Thyroid Microcarcinoma With BRAF V600E Mutation.
    J Clin Endocrinol Metab. 2023 May 23:dgad269. doi: 10.1210.
    >> Share

  108. CHOU CK, Chi SY, Hung YY, Yang YC, et al
    Clinical impact of androgen receptor-suppressing miR-146b expression in papillary thyroid cancer aggressiveness.
    J Clin Endocrinol Metab. 2023 May 23:dgad279. doi: 10.1210.
    >> Share

  109. ALZAHRANI AS
    Clinical use of molecular data in thyroid nodules and cancer.
    J Clin Endocrinol Metab. 2023 May 18:dgad282. doi: 10.1210.
    >> Share

  110. SUN Y, Sun Q, Tian J, He X, et al
    Impact of waiting time for radioactive iodine therapy on outcome in N1 stage papillary thyroid cancer.
    J Clin Endocrinol Metab. 2023 May 11:dgad264. doi: 10.1210.
    >> Share

    April 2023
  111. ULLMANN TM, Sosa JA
    Delay in Surgery for Papillary Thyroid Cancer: A Proxy for Lower-Quality Care?
    J Clin Endocrinol Metab. 2023 Apr 21:dgad232. doi: 10.1210.
    >> Share

  112. CHIOSEA S, Hodak SP, Yip L, Abraham D, et al
    Molecular Profiling of 50,734 Bethesda III-VI Thyroid Nodules by ThyroSeq v3: Implications for Personalized Management.
    J Clin Endocrinol Metab. 2023 Apr 18:dgad220. doi: 10.1210.
    >> Share

    March 2023
  113. ALZAHRANI AS
    The risk of expanding risk stratification in thyroid cancer.
    J Clin Endocrinol Metab. 2023 Mar 29:dgad182. doi: 10.1210.
    >> Share

  114. CHAVES N, Broekhuis JM, Fligor SC, Collins RA, et al
    Delay in Surgery and Papillary Thyroid Cancer Survival in the United States: a SEER-Medicare Analysis.
    J Clin Endocrinol Metab. 2023 Mar 29:dgad163. doi: 10.1210.
    >> Share

  115. VAN VELSEN EFS, Verburg FA
    Adjuvant Radioiodine for Intermediate-Risk Papillary Thyroid Cancer - To Treat or Not To Treat.
    J Clin Endocrinol Metab. 2023 Mar 25:dgad171. doi: 10.1210.
    >> Share

  116. KESBY N, Mechera R, Fuchs T, Papachristos A, et al
    Natural History and Predictive Factors of Outcome in Medullary Thyroid Microcarcinoma.
    J Clin Endocrinol Metab. 2023 Mar 25:dgad173. doi: 10.1210.
    >> Share

  117. NASR CE
    Can one predict long-term growth of cytologically-benign thyroid nodules?
    J Clin Endocrinol Metab. 2023 Mar 22:dgad160. doi: 10.1210.
    >> Share

  118. JHA S, Welch J, Tora R, Lack J, et al
    Germline and somatic inactivating FLCN variants in parathyroid cancer and atypical parathyroid tumors.
    J Clin Endocrinol Metab. 2023 Mar 20:dgad136. doi: 10.1210.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016